Leap Therapeutics reports Q2 EPS (52c), consensus (43c)

Cash and cash equivalents totaled $78.5M at June 30, 2024. “With the momentum provided by our $40M private placement, we are positioned to achieve our critical company milestones,” said Douglas E. Onsi, President and CEO of Leap. “We have executed well on our two DKN-01 randomized controlled trials and on preparatory activities for registrational studies. We look forward to sharing initial data from both randomized controlled studies over the next 12 months as we strive to deliver new treatments for patients fighting against cancer.”